Haloperidol (HP) is widely used in the treatment of several forms of psychosis. Despite of its efficacy, HP use is a cause of concern for the elevated risk of adverse drug reactions. adverse drug reactions risk and HP efficacy greatly vary across subjects, indicating the involvement of several factors in HP mechanism of action. The use of biomarkers that could monitor or even predict HP treatment impact would be of extreme importance. We reviewed the elements that could potentially be used as peripheral biomarkers of HP effectiveness. Although a validated biomarker still does not exist, we underlined the several potential findings (e.g., about cytokines, HP metabolites and genotypic biomarkers) which could pave the way for future research on HP biomarkers.

Porcelli, S.L., Crisafulli, C., Calabro', M., Serretti, A., Rujescu, D. (2016). Possible biomarkers modulating haloperidol efficacy and/or tolerability. PHARMACOGENOMICS, 17(5), 507-529 [10.2217/pgs.16.5].

Possible biomarkers modulating haloperidol efficacy and/or tolerability

PORCELLI, STEFANO LUIGI;CRISAFULLI, CONCETTA;CALABRO', MARCO;SERRETTI, ALESSANDRO;
2016

Abstract

Haloperidol (HP) is widely used in the treatment of several forms of psychosis. Despite of its efficacy, HP use is a cause of concern for the elevated risk of adverse drug reactions. adverse drug reactions risk and HP efficacy greatly vary across subjects, indicating the involvement of several factors in HP mechanism of action. The use of biomarkers that could monitor or even predict HP treatment impact would be of extreme importance. We reviewed the elements that could potentially be used as peripheral biomarkers of HP effectiveness. Although a validated biomarker still does not exist, we underlined the several potential findings (e.g., about cytokines, HP metabolites and genotypic biomarkers) which could pave the way for future research on HP biomarkers.
2016
Porcelli, S.L., Crisafulli, C., Calabro', M., Serretti, A., Rujescu, D. (2016). Possible biomarkers modulating haloperidol efficacy and/or tolerability. PHARMACOGENOMICS, 17(5), 507-529 [10.2217/pgs.16.5].
Porcelli, STEFANO LUIGI; Crisafulli, Concetta; Calabro', Marco; Serretti, Alessandro; Rujescu, Dan
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/585584
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact